Batoclimab is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). HanAll Biopharma Co., Ltd. originally developed Batoclimab and licensed it to Harbour BioMed in 2017 under a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results